(Q51646400)

8 April 2018

title

Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment. (English)

1 reference

8 April 2018

0 references

1

1 reference

8 April 2018

Reinhard Guthke

6

object named as

R Guthke

1 reference

8 April 2018

author name string

R H Goertsches

2

1 reference

8 April 2018

C Fatum

3

1 reference

8 April 2018

D Koczan

4

1 reference

8 April 2018

H-J Thiesen

5

1 reference

8 April 2018

U K Zettl

7

1 reference

8 April 2018

publication date

19 October 2010

1 reference

8 April 2018

The Pharmacogenomics Journal

published in

1 reference

8 April 2018

volume

12

1 reference

8 April 2018

issue

2

1 reference

8 April 2018

page(s)

134-146

1 reference

8 April 2018

https://scigraph.springernature.com/pub.10.1038/tpj.2010.77

exact match

0 references

cites work

The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

How cells respond to interferons revisited: from early history to current complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Genomic effects of IFN-beta in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Clinical characteristics of responders to interferon therapy for relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Genomics in multiple sclerosis--current state and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Gene regulatory network inference: data integration in dynamic models-a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Reverse engineering of gene regulatory networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Novel definition files for human GeneChips based on GeneAnnot

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Integrative modeling of transcriptional regulation in response to antirheumatic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Using GOstats to test gene lists for GO term association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

STAMP: a web tool for exploring DNA-binding motif similarities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

21 January 2018

Least angle regression

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Power-Law Distributions in Empirical Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Differential regulation of the OASL and OAS1 genes in response to viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Cloning and functional expression of a new aquaporin (AQP9) abundantly expressed in the peripheral leukocytes permeable to water and urea, but not to glycerol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Interferon beta-1a counteracts effects of activation on the expression of G-protein-coupled receptor kinases 2 and 3, beta-arrestin-1, and regulators of G-protein signalling 2 and 16 in human mononuclear leukocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Following a TRAIL: update on a ligand and its five receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Molecular properties of Zic proteins as transcriptional regulators and their relationship to GLI proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Gene expression profiles reveal homeostatic dynamics during interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Interferon-beta directly influences monocyte infiltration into the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Endothelial cell specific adhesion molecule (ESAM) localizes to platelet-platelet contacts and regulates thrombus formation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Targeted disruption of endothelial cell-selective adhesion molecule inhibits angiogenic processes in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

The role of junctional adhesion molecules in vascular inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Can we predict flu-like symptoms in patients with multiple sclerosis treated with interferon-beta?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Regulation of ANKRD9 expression by lipid metabolic perturbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.77

21 January 2018

Identifiers

DOI

10.1038/TPJ.2010.77

1 reference

8 April 2018

PubMed ID

20956993

1 reference

8 April 2018